Gabrail Cancer Center

Dover, Ohio 44622

0 studies enrolling now · 5 studies all time

What they study most

B-Cell Lymphoma, Carcinoma, Non-Small Cell Lung, DLBCL Transformed From Indolent Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Grade 3 Lymphoma, Metastatic Breast Cancer, Solid Tumors, de Novo DLBCL

Studies at this site

• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant — Completed
• A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer — Completed
• Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) — Completed
• Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors — Completed
• Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy — Stopped early